



## **Endocan Changes Name to Nirvana Life Sciences and Expects to Trade on CSE**

**March 14, 2022 – Vancouver, British Columbia – Nirvana Life Sciences Inc.** (the “Company”), formerly Endocan Solutions Inc., announces that it has received conditional approval for the listing of the Company’s common shares on the CSE, subject to the completion of certain requirements, which have all been satisfied. The Company anticipates that its common shares will commence trading on the CSE under the symbol “NIRV” on March 17, 2022.

Concurrent with its CSE listing, the Company will close its previously announced acquisition (the “Reverse Takeover”) of 1253766 B.C. Ltd. (the “Target”), formerly Nirvana Life Sciences Inc, by issuing 25,905,095 common shares of the Company as consideration for 25,905,095 common shares of the Target. In connection with the Reverse Takeover, the Company has changed its name to “Nirvana Life Sciences Inc.” and the Target has changed its name to 1253766 B.C. Ltd.

After closing of the Reverse Takeover, the Company will be proceeding with its plan to carry on the business of the Target, the research and development of novel formulations of psilocybin and other naturally sourced psychedelics to treat pain, opioid dependency and other health problems. The Company’s leadership team will be composed of the following individuals:

- Bruce Clark, Chief Executive Officer and Director
- Connie Hang, Chief Financial Officer
- Dr. Sazzad Hossain, Chief Technical Officer
- Michael McCune, Chief Operating Officer
- Chris Hoffmeister, Director
- Edward Lupton, Director
- Mark Marissen, Director
- Annie Storey, Director

### About Nirvana Life Sciences Inc.

Nirvana Life Sciences Inc. is focused on developing medical products and regimens that address addiction. Nirvana is working on novel formulations of psilocybin and other naturally sourced psychedelics to treat pain, opioid dependency and other health problems. Learn more at [nirvanalifescience.com](http://nirvanalifescience.com)

For more information, please contact

Bruce Clark, CEO

Tel: (604) 401-8100

Email: [info@nirvanalifescience.com](mailto:info@nirvanalifescience.com)

This news release contains statements (such statements hereinafter referred to as “Forward-Looking Information”) regarding possible events, conditions or financial performance related to or affecting the “Company” that is based on assumptions about future economic conditions and courses of action, and includes future-oriented financial information with respect to the Company’s prospective financial performance, financial position or cash flows which may be presented as a forecast or a projection. Forward-Looking Statements in this «presentation/document» include but is not limited to the closing of the transactions described in this news release and Nirvana’s anticipated listing on the CSE and the timing thereof. Forward-Looking Statements require the Company to make assumptions and are subject to inherent risks and uncertainties, which give rise to the possibility that the predictions, forecasts, projections, expectations or conclusions expressed or implied by the Forward-Looking Statements will not prove to be true or accurate. You are cautioned not to place undue reliance on these statements as a number of factors could cause the Company’s actual results to differ materially from the expectations expressed in such Forward-Looking Statements. Except as required by law, the Company does not undertake to update any Forward-Looking Statement, whether written or oral, that may be made from time to time by the Company or on its behalf.